艾塞那肽长效缓释微球的制备及体内药效学研究.doc

艾塞那肽长效缓释微球的制备及体内药效学研究.doc

  1. 1、本文档共10页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
艾塞那肽长效缓释微球的制备及体内药效学研究

艾塞那肽长效缓释微球的制备及体内药效学研究 刘斌1,2,董庆光1,王梦舒1,李纯1,孔维1,2,陈妍1* (1.吉林大学生命科学学院,长春 130012; 2.吉林大学超分子结构与材料国家重点实验室,长春 130012.) 摘要:目的 制备艾塞那肽长效缓释微球,并考察其理化性质、体外释放特性及体内药效学。方法 采用复乳-溶剂挥发法(W/O/W)制备包裹艾塞那肽的聚乳酸-羟基乙酸嵌段共聚物(PLGA)微球;考察微球的粒径分布、表面形态、载药量和包封率; 用micro-BCA试剂盒测定微球的体外释放速率;考察了微球在糖尿病模型小鼠体内的降血糖作用。结果 微球外观光滑圆整,分散性好,艾塞那肽载药量为3%,包封率为75%;微球40d之内体外累积释放达到88%,其体外释放曲线近似零级释放模式;体内药效学实验结果显示,40d内微球组小鼠与模型对照组小鼠血糖相比具有显著性差异(P0.05)。结论 采用复乳-溶剂挥发法成功制备了可以缓释40d的艾塞那肽长效微球,且40d之内在糖尿病小鼠体内具有明显的降血糖作用。 关键词:艾塞那肽;聚乳酸-羟基乙酸嵌段共聚物;微球;血糖 中图文类号: 文献标识码: 文章编号: Preparation of Long-acting Release Microspheres of Exenatide and Studies on Their in vivo Pharmacodynamics LIU Bin1,2,DONG Qing-Guang,WANG Meng-Shu,LI Chun,KONG Wei,CHEN Yan* (1. College of Life Science, Jilin University, Changchun 130012, China; 2. State Key Laboratory Supramolecular Structure Materials, Jilin University, Changchun 130012.,China.) ABSTRACT: OBJECTIVE To prapere Exenatide loaded long-acting release microspheres, and to evaluate their physical and chemical characteristics、in vitro release behavior as well as in vivo pharmacodynamics. METHOD Exenatide loaded PLGA microspheres were prepared by double emulsion(W/O/W)method. The mean diameter、morphology、drug loading and encapsulation efficiency were evaluated. The micro-BCA protein assay was used for the in vitro release behavior. The effect of reducing plasma glucose were evaluated on the diabetes mice. RESULTS The microspheres possessed smooth and round appearance as well as good dispersive quality. The drug loading and encapsulation efficiency was 3% and 75%. The in vitro accumulated release within 40d reached up to 88%, and the release profile is consistent with zero-class release model. The results of in vivo pharmacodynamics indicated that the plasma glucose of mice injected with Exenatide microspheres was different significantly from the plasma glucose of the diabetes model mice within 40d (P0.05). CONCLUSION The Exenatide loaded long-acting release microspheres which could yield

文档评论(0)

youshen + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档